{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:18:56Z","timestamp":1790014736207,"version":"4.0.1"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Microbiology and Immunology"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to compare the efficacy of valaciclovir, valganciclovir, and artesunate in treating chronic reactivated human herpesvirus type 6 (HHV\u20106) and human herpesvirus type 7 (HHV\u20107) infection associated with myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS). From 255 patients (192 cases) with reactivated HHV\u20106 and HHV\u20107 infections (confirmed based on blood leukocyte PCR), valaciclovir, valganciclovir, or artesunate was administered at a dose of 3000, 900, and 100\u2009mg\/day, respectively, for 3 months (study group). The control group consisted of similar patients with ME\/CFS (<jats:italic>n<\/jats:italic> = 63) not taking any antiviral drugs. The significance of differences was evaluated by Student's <jats:italic>t<\/jats:italic>\u2010test and the nonparametric criterion\u2014the number of <jats:italic>Z<\/jats:italic>\u2010signs. Negative PCR results in patients with HHV\u20106 and HHV\u20107 treated with valaciclovir was achieved in 26% and 23% (first month), 34%, and 28% (second month), 37% and 34% of cases (third month), respectively (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05; <jats:italic>Z<\/jats:italic>\u2009&lt;\u2009<jats:italic>Z<\/jats:italic><jats:sub>0.05<\/jats:sub>). The same results with valganciclovir were obtained in 35% and 33% (first month), 44% and 39% (second month), 48% and 45% of cases (third month), but with artesunate in 44% and 41% (first month), 57% and 53% (second month), 68% and 63% of cases (third month), respectively (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05; <jats:italic>Z<\/jats:italic>\u2009&lt;\u2009<jats:italic>Z<\/jats:italic><jats:sub>0.05<\/jats:sub>). Artesunate is more effective than valganciclovir and valacyclovir in patients with ME\/CFS with reactivated HHV\u20106 and HHV\u20107 infections.<\/jats:p>","DOI":"10.1111\/1348-0421.12966","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T06:24:17Z","timestamp":1643696657000},"page":"193-199","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A comparative study of valaciclovir, valganciclovir, and artesunate efficacy in reactivated HHV\u20106 and HHV\u20107 infections associated with chronic fatigue syndrome\/myalgic encephalomyelitis"],"prefix":"10.1111","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6615-3072","authenticated-orcid":false,"given":"Dmitry","family":"Maltsev","sequence":"first","affiliation":[{"name":"Laboratory of Immunology and Molecular Biology, Research Institute of Experimental and Clinical Medicine O'Bogomolets National Medical University Kyiv Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.07.004"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184171"},{"issue":"3","key":"e_1_2_10_4_1","first-page":"179","article-title":"Frequent HHV\u20106 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients","volume":"16","author":"Ablashi DV","year":"2000","journal-title":"J Med Virol"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01400"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24810"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199104000-00004"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(06)70011-7"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/205085"},{"issue":"1","key":"e_1_2_10_10_1","first-page":"4","article-title":"Valacyclovir treatment of chronic fatigue in adolescents","volume":"28","author":"Henderson TA","year":"2014","journal-title":"Adv MindBody Med"},{"issue":"5","key":"e_1_2_10_11_1","first-page":"707","article-title":"Valacyclovir treatment in Epstein\u2010Barr virus subset chronic fatigue syndrome: thirty\u2010six months follow\u2010up","volume":"21","author":"Lerner AM","year":"2007","journal-title":"In Vivo"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(06)70009-9"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23713"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23411"},{"key":"e_1_2_10_15_1","unstructured":"GottschalkG BaraoI PetersonDTherapeutic potential of cidofovir (HPMPC VISTIDE) for the treatment of HHV\u20106 and\/or CMV infections in severely ill patients diagnosed with chronic fatigue syndrome\/myalgic encephalomyelitis. In: HHV\u20106\/7 International Conference. Paris: Program Book;2013 pp.57\u201360."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2018.01.004"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2009.05.017"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.46"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.15391"},{"key":"e_1_2_10_20_1","volume-title":"Statistical analysis in biological and medical research","author":"Urbach VY","year":"1975"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2011.03.005"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.014116"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-2-103"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020475108745"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25744"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.656692"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.6.1660-1661.1995"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.2000006"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1051\/e3sconf\/202015908007"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/172.5.1364"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1159\/000517930"},{"issue":"1","key":"e_1_2_10_32_1","first-page":"174","article-title":"Artesunate for the treatment of severe malaria: a retrospective review of patients admitted to two tertiary hospital intensive care units in Johannesburg, South Africa","volume":"35","author":"Tadzimirwa R","year":"2020","journal-title":"S Afr J Infect Dis"}],"container-title":["Microbiology and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1348-0421.12966","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1348-0421.12966","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1348-0421.12966","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T18:18:41Z","timestamp":1692987521000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1348-0421.12966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1111\/1348-0421.12966"],"URL":"https:\/\/doi.org\/10.1111\/1348-0421.12966","archive":["Portico"],"relation":{},"ISSN":["0385-5600","1348-0421"],"issn-type":[{"value":"0385-5600","type":"print"},{"value":"1348-0421","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]},"assertion":[{"value":"2021-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}